This strategic partnership and investment allows Kailos to continue the development of NGS laboratory and software solutions that may benefit the intelligence community.
“Kailos Genetics’ combination of genomic technologies represents an approach that is unique in the marketplace,” said Tom Gillespie, Investment Partner at IQT. “We believe that further development of this technology will provide valuable capabilities for both the public and private sector.”
“We’re excited to partner with IQT to continue our development of solutions for the identification of genetic materials,” said Troy Moore, Chief Scientific Officer of Kailos Genetics. “This partnership will foster positive outcomes for the intelligence community.”
To learn more about Kailos Genetics, visit www.kailossolutions.com.
Kailos Genetics is an innovator in next-generation sequencing technologies, with best-in-class target enrichment chemistries combined with proprietary analysis and reporting software for a complete solution. TargetRich™ provides a simple work flow with robust performance for superior analytic results for next-generation sequencing assays. Kailos Blue is a proprietary, modular laboratory information system with modules for managing samples in the laboratory environment, analytics, and full reporting. Founded in 2010, and based in Huntsville’s HudsonAlpha Institute for Biotechnology, Kailos is committed to providing a simple, trusted and affordable solution to laboratories looking to launch next-generation sequencing solutions. To learn more, visit www.kailossolutions.com.
IQT is the non-profit strategic investor that accelerates the development and delivery of cut-ting-edge technologies to U.S. government agencies that keep our nation safe. IQT was established in 1999 with a distinct mission: to identify and collaborate with startup companies developing innovative technologies that protect and preserve our nation’s security. Visit www.iqt.org for more information.